For instance, by arming an oncolytic adenovirus designed to express TNF‐related apoptosis‐inducing ligand (TRAIL), the overexpression of TRAIL increases the oncolytic potency of adenovirus via promoting apoptotic cell death in vitro and in vivo.[29, 30] TRAIL causes apoptosis primarily in cancer cells through ligation to specific death receptors.[31] The unique feature of oncolytic virotherapy is the lysis of tumor cells without damage to normal cells, which can make this method a targeted treatment in cancer therapy.[32]. This evidence concerns the gene TNFSF10 and cancer.